Four IPOs are scheduled to raise $1.8 billion in the shortened holiday week, featuring a diverse group of foreign issuers. China’s leading e-cigarette brand RLX Technology (RLX) plans to raise $1.0 billion at a $14.0 billion market cap. RLX...read more
Seven IPOs and five SPACs entered public markets this past week, led by high-flying Jamf Holding (JAMF) and the largest SPAC ever Pershing Square Tontine Holdings (PSTHU). Four sizable biotechs all priced at the high end of the range or above, but returned...read more
iTeos Therapeutics, a Phase 1/2 immuno-oncology biotech developing therapies for various cancers, raised $201 million by offering 10.6 million shares at $19, above the range of $16 to $18. The company originally planned to offer 8.9 million shares. At pricing,...read more
iTeos Therapeutics, a Phase 1/2 immuno-oncology biotech developing therapies for various cancers, announced terms for its IPO on Monday.
The Cambridge, MA-based company plans to raise $151 million by offering 8.9 million shares at a price range of $16 to $18....read more
US IPO Week Ahead: Foreign issuers dominate a 4 IPO week
Four IPOs are scheduled to raise $1.8 billion in the shortened holiday week, featuring a diverse group of foreign issuers. China’s leading e-cigarette brand RLX Technology (RLX) plans to raise $1.0 billion at a $14.0 billion market cap. RLX...read more
US IPO Weekly Recap: Software and SPACs shine in a 7 IPO week
Seven IPOs and five SPACs entered public markets this past week, led by high-flying Jamf Holding (JAMF) and the largest SPAC ever Pershing Square Tontine Holdings (PSTHU). Four sizable biotechs all priced at the high end of the range or above, but returned...read more
Immuno-oncology biotech iTeos Therapeutics prices upsized IPO at $19, above the range
iTeos Therapeutics, a Phase 1/2 immuno-oncology biotech developing therapies for various cancers, raised $201 million by offering 10.6 million shares at $19, above the range of $16 to $18. The company originally planned to offer 8.9 million shares. At pricing,...read more
Oncology biotech iTeos Therapeutics sets terms for $151 million IPO
iTeos Therapeutics, a Phase 1/2 immuno-oncology biotech developing therapies for various cancers, announced terms for its IPO on Monday. The Cambridge, MA-based company plans to raise $151 million by offering 8.9 million shares at a price range of $16 to $18....read more